FDA OKs first cannabinoid, gives green light to GW Pharma’s Epidiolex for rare seizures
GW Pharma $GWPH finished its layup at the FDA today with Epidiolex, grabbing its first ever marketing OK for one of its cannabinoid drugs and setting up the biotech for a major shift toward commercialization.
Two months after a unanimous recommendation by an outside group of FDA experts and some glowing recommendations in the internal review, GW will now set out to open up a new class of meds after demonstrating the drug’s ability to prevent seizures in children suffering from rare cases of Lennox-Gastaut syndrome and Dravet syndrome.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
